SWITCH SWEDEHEART
2026
Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome — a Stepped Wedge Cluster Randomized Evaluation in the SWEDEHEART-registry (SWITCH SWEDEHEART)
In 17,095 patients with an acute coronary syndrome, prasugrel as the default P2Y12 inhibitor did not reduce death, myocardial infarction or stroke at 1 year compared with ticagrelor.
Risultato
Efficacia: Cumulative 1-year risk of the composite of death, myocardial infarction or strokeadjusted OR 0,90 (IC 95% 0,77-1,06)
Sicurezza: Major bleedingOR 0,80 (IC 95% 0,64-0,99)
Sotto 1 a favore di prasugrel as the default P2Y12 inhibitor, sopra 1 a favore di ticagrelor.
Tassi di eventi Prasugrel as the default P2Y12 inhibitor 11,1% vs ticagrelor 11,8% (cumulative 1-year risk of the composite of death, myocardial infarction or stroke)
Riportato inoltre: No difference in the individual components.
- Sottotema
- P2Y12 inhibitor choice
- Disegno
- Registry-based (SWEDEHEART), prospective, multicentre, open-label, stepped-wedge cluster-randomised trial; Swedish administrative regions form the clusters; all clusters start with ticagrelor as the default P2Y12 inhibitor and the order in which clusters switch to prasugrel as default is randomly assigned, one cluster switching every 9 months; outcomes captured through national registries with 1-year follow-up
- Rilevanza
- Importante: uno dei diversi pilastri.
- Fonte
- Omerovic E, et al. N Engl J Med. 2026; published online 29 August.doi 10.1056/nejmoa2609057
Discussione e critica
A stepped-wedge registry trial tests a regional default, not a drug in an individual patient, and that is its strength: 17,095 consecutive patients including the elderly, prior stroke and an indication for anticoagulation, the people conventional antiplatelet trials exclude. The ischaemic composite is neutral and its interval spans a 23% reduction to a 6% increase. The bleeding advantage is the finding people will quote, and its upper bound is 0.99: one event either way and it disappears.